RANI
Rani Therapeutics Holdings, Inc.Company Information
- Company Name
- Rani Therapeutics Holdings, Inc.
- CIK
- CIK0001856725
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- RANI: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- RANI
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-21
- Last sale
- 2026-03-27
- Shares purchased (TTM)
- 2,154,334
- Shares sold (TTM)
- 4,000,386
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 45,248,251
- Shares outstanding
- 187,168,000
- Ownership
- 24.18%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 8.40%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Class A | 0 | - | - | -0 | -33 | 34 | - | 0 | 3 | - | - | - | ||||||
| Common Class B | 0 | - | - | -24 | -0 | 24 | - | 0 | 24 | - | - | - | ||||||
| Common Class C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 5 | 10 | 19 | 4 | 10 | 10 | 4 | 4 | 5 | 7 | 6 | 5 | ||||||
| Accounts Receivable Net Current | 2 | 2 | 2 | - | - | 1 | 0 | - | - | - | - | - | ||||||
| Contract With Customer Asset Net Current | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Marketable Securities | 49 | 34 | 31 | 0 | 0 | 6 | 24 | 26 | 26 | 33 | 43 | 56 | ||||||
| Prepaid Expense Current | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 | 3 | ||||||
| Assets Current | 57 | 47 | 53 | 5 | 11 | 18 | 30 | 32 | 32 | 41 | 51 | 63 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 5 | 6 | 6 | 6 | 6 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Assets | 61 | 52 | 59 | 10 | 17 | 24 | 37 | 44 | 44 | 54 | 58 | 70 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 0 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | ||||||
| Accrued Liabilities And Other Liabilities | 3 | 5 | 4 | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 2 | 4 | ||||||
| Deferred Revenue | - | - | - | - | - | - | - | 1 | - | - | - | - | ||||||
| Deferred Revenue Current | 5 | 7 | 7 | - | - | - | 0 | - | - | - | - | - | ||||||
| Long Term Debt Current | - | - | 0 | 14 | 15 | 15 | 15 | 15 | 12 | 9 | 5 | 1 | ||||||
| Operating Lease Liability Current | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 11 | 14 | 13 | 19 | 21 | 20 | 20 | 20 | 17 | 13 | 8 | 7 | ||||||
| Deferred Revenue Noncurrent | 0 | 0 | 2 | - | - | - | 0 | - | - | - | - | - | ||||||
| Long Term Debt Noncurrent | - | - | 0 | 0 | 2 | 6 | 10 | 14 | 17 | 21 | 24 | 28 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 0 | 0 | ||||||
| Liabilities | 13 | 16 | 17 | 22 | 26 | 29 | 33 | 38 | 38 | 39 | 32 | 36 | ||||||
Members Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 186 | 168 | 166 | 114 | 111 | 107 | 105 | 97 | 90 | 88 | 86 | 83 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -147 | -140 | -133 | -122 | -117 | -110 | -103 | -94 | -87 | -80 | -73 | -66 | ||||||
| Stockholders Equity | 39 | 28 | 33 | -12 | -9 | -5 | 3 | 6 | 3 | 15 | 13 | 35 | ||||||
| Minority Interest | 9 | 7 | 9 | -4 | -4 | -2 | 2 | 3 | 3 | 7 | 13 | 17 | ||||||
| Liabilities And Stockholders Equity | 61 | 52 | 59 | 10 | 17 | 24 | 37 | 44 | 44 | 54 | 58 | 70 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRani Therapeutics Holdings, Inc. (RANI) — SEC Financial Statements & Analysis
Rani Therapeutics Holdings, Inc. (RANI) is a pharmaceutical preparations company, incorporated in CA. Rani Therapeutics Holdings, Inc. trades on Nasdaq as: RANI. Rani Therapeutics Holdings, Inc. (RANI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Rani Therapeutics Holdings, Inc. carries a market cap of $142.25M, a P/E ratio of -6.74x, a P/B ratio of 3.63x, a P/S ratio of 29.17x, an enterprise value of $137.18M, and an EV/EBITDA multiple of -4.26x. On profitability, it posts an operating margin of -675.80%, a net margin of -432.99%, a Return on Equity (ROE) of -140.40%, a Return on Assets (ROA) of -54.33%, and a Return on Invested Capital (ROIC) of -208.29%. Per share, it reports EPS of $-0.11, diluted EPS of $-0.11, free cash flow per share of $-0.11, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 306.42% year-over-year, net income growth of -59.70% year-over-year, and EPS growth of -92.13% year-over-year. On the balance sheet, it maintains a current ratio of 5.31x, a quick ratio of 5.21x, working capital of $45.88M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.21, an interest coverage ratio of -28.24x, free cash flow of $-20.34M (TTM), and net debt of $-5.07M. Figures sourced from SEC EDGAR.
- Market Cap
- $142.25M
- P/E TTM
- -6.74x
- EPS TTM
- $-0.11
- P/B TTM
- 3.63x
- ROE TTM
- -140.40%
- ROA TTM
- -54.33%
- Debt To Equity
- 0.33x
- Free Cash Flow TTM
- $-20.34M
- Net Revenue TTM Growth 1Y
- 306.42%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Rani Therapeutics Holdings, Inc. in?
Rani Therapeutics Holdings, Inc. (RANI) operates in the Pharmaceutical Preparations industry.
What exchange does RANI trade on?
Rani Therapeutics Holdings, Inc. (RANI) trades on the Nasdaq.
Where is Rani Therapeutics Holdings, Inc. incorporated?
Rani Therapeutics Holdings, Inc. is incorporated in CA.
When was Rani Therapeutics Holdings, Inc. (RANI)'s most recent SEC filing?
Rani Therapeutics Holdings, Inc. (RANI)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is RANI's market cap?
Rani Therapeutics Holdings, Inc. (RANI) has a market capitalization of $142.25M as of 2026-06-30.
What is RANI's EPS (earnings per share)?
Rani Therapeutics Holdings, Inc. (RANI)'s trailing twelve month EPS is $-0.11 as of 2026-06-30.
What is RANI's ROE (return on equity)?
Rani Therapeutics Holdings, Inc. (RANI)'s trailing twelve month Return on Equity (ROE) is -140.40% as of 2026-06-30.
What is RANI's ROA (return on assets)?
Rani Therapeutics Holdings, Inc. (RANI)'s trailing twelve month Return on Assets (ROA) is -54.33% as of 2026-06-30.
What is RANI's ROIC (return on invested capital)?
Rani Therapeutics Holdings, Inc. (RANI)'s trailing twelve month Return on Invested Capital (ROIC) is -208.29% as of 2026-06-30.
What is RANI's EV/EBITDA?
Rani Therapeutics Holdings, Inc. (RANI)'s trailing twelve month EV/EBITDA is -4.26x as of 2026-06-30.